TANDEARIL Drug Patent Profile

When do Tandearil patents expire, and what generic alternatives are available?

Tandearil is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in TANDEARIL is oxyphenbutazone. There is one drug master file entry for this compound. Additional details are available on the oxyphenbutazone profile page.

Summary for TANDEARIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	58
Patent Applications:	5,283
DailyMed Link:	TANDEARIL at DailyMed

US Patents and Regulatory Information for TANDEARIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TANDEARIL	oxyphenbutazone	TABLET;ORAL	012542-004	Sep 3, 1982		DISCN	No	No

TANDEARIL (OXYPHENBUTAZONE): MARKET DYNAMICS AND FINANCIAL TRAJECTORY

Last updated: February 19, 2026

WHAT IS TANDEARIL AND WHAT IS ITS PRIMARY THERAPEUTIC USE?

TANDEARIL is the brand name for oxyphenbutazone, a nonsteroidal anti-inflammatory drug (NSAID). Its primary therapeutic use has been for the treatment of inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and gout. Oxyphenbutazone acts by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins, which are key mediators of inflammation, pain, and fever.

WHAT IS THE CURRENT REGULATORY STATUS AND MARKET PRESENCE OF TANDEARIL?

Oxyphenbutazone, marketed as TANDEARIL, has been largely withdrawn from major pharmaceutical markets due to safety concerns. The U.S. Food and Drug Administration (FDA) approved oxyphenbutazone in 1959. However, by the 1980s, reports of serious adverse events, including aplastic anemia, agranulocytosis, and gastrointestinal hemorrhage, led to its voluntary withdrawal by the manufacturer.

In Europe, many national regulatory agencies have also delisted oxyphenbutazone. For instance, it is not currently authorized for use in the European Union according to the European Medicines Agency (EMA) database. In some countries, it may still be available through specific import channels or as a compounded medication, but its widespread prescription and availability are severely restricted or nonexistent.

WHAT ARE THE KEY ADVERSE EVENTS ASSOCIATED WITH TANDEARIL?

The significant adverse events linked to oxyphenbutazone have led to its market decline. These include:

• Hematological Abnormalities: Severe and potentially fatal blood dyscrasias such as aplastic anemia and agranulocytosis have been a primary concern. These conditions involve the bone marrow's failure to produce sufficient blood cells.
• Gastrointestinal Complications: Like other NSAIDs, oxyphenbutazone can cause serious gastrointestinal issues, including bleeding, ulceration, and perforation of the stomach and intestines.
• Cardiovascular Risks: While less prominently cited than hematological issues, NSAIDs in general are associated with increased risk of cardiovascular thrombotic events, myocardial infarction, and stroke.
• Renal Toxicity: NSAID use can lead to renal impairment, particularly in patients with pre-existing kidney disease.
• Hepatic Toxicity: Liver dysfunction has also been reported.
• Hypersensitivity Reactions: Allergic reactions and skin rashes can occur.

These safety profiles are detailed in post-marketing surveillance and clinical reviews that have impacted its regulatory standing and commercial viability.

WHAT WAS THE PEAK MARKET SHARE AND REVENUE GENERATED BY TANDEARIL?

Quantifying the exact peak market share and revenue for TANDEARIL is challenging due to the historical nature of its widespread use and the lack of readily accessible historical sales data from the period of its peak commercial activity (primarily the 1960s and 1970s). Sales data from that era is not as comprehensively digitized or publicly disclosed as current pharmaceutical sales figures.

However, during its active market life, TANDEARIL was a significant player in the anti-inflammatory market. It competed directly with other NSAIDs and older anti-inflammatory agents. Its efficacy in treating chronic inflammatory conditions like rheumatoid arthritis contributed to its substantial prescription volume.

Given its widespread availability and prescription rates before the emergence of safety concerns, it is estimated that TANDEARIL likely generated revenues in the tens to potentially low hundreds of millions of dollars annually during its peak years. Its market share within the NSAID category would have been considerable, second only to perhaps aspirin in terms of broad anti-inflammatory indications.

The drug's decline was not a gradual phasing out due to competitive obsolescence but rather a precipitous fall driven by safety warnings and regulatory actions. This suggests that its revenue trajectory was sharply curtailed rather than slowly declining.

WHAT ARE THE ALTERNATIVE TREATMENTS AVAILABLE FOR CONDITIONS PREVIOUSLY MANAGED BY TANDEARIL?

The therapeutic landscape for inflammatory conditions has evolved significantly, offering numerous alternatives to oxyphenbutazone. These include:

• Other NSAIDs: A broad class of drugs with varying potency and safety profiles. Examples include ibuprofen (e.g., Advil, Motrin), naproxen (e.g., Aleve, Naprosyn), diclofenac (e.g., Voltaren), and celecoxib (e.g., Celebrex), a COX-2 selective inhibitor designed to reduce gastrointestinal side effects.
• Disease-Modifying Antirheumatic Drugs (DMARDs): These drugs target the underlying immune system dysfunction in inflammatory conditions like rheumatoid arthritis. They include conventional synthetic DMARDs (e.g., methotrexate, sulfasalazine, leflunomide), targeted synthetic DMARDs (e.g., JAK inhibitors like tofacitinib), and biologic DMARDs (e.g., TNF inhibitors like adalimumab, etanercept; IL-6 inhibitors like tocilizumab).
• Corticosteroids: Potent anti-inflammatory agents (e.g., prednisone, methylprednisolone) used for rapid symptom control and during flares, but typically not for long-term monotherapy due to significant side effects.
• Analgesics: Acetaminophen (paracetamol) is used for pain management and fever reduction, though it lacks significant anti-inflammatory properties.
• Topical Treatments: For localized pain and inflammation, topical NSAIDs or other agents can be employed.

The availability of these diverse treatment options, with improved safety profiles and targeted mechanisms of action, has rendered oxyphenbutazone largely obsolete in standard clinical practice.

WHAT ARE THE INTELLECTUAL PROPERTY CONSIDERATIONS FOR TANDEARIL?

The original patents for oxyphenbutazone, including those covering its synthesis and formulation as TANDEARIL, would have expired decades ago. Oxyphenbutazone was first synthesized in the 1940s, and its therapeutic applications were established in the mid-20th century.

• Original Patents: Expired in the late 20th century.
• Exclusivity: No market exclusivity or patent protection exists for oxyphenbutazone itself.
• Generic Availability: If a market existed for oxyphenbutazone, it would be entirely subject to generic competition.
• New Formulations/Indications: Development of novel formulations or new therapeutic uses for oxyphenbutazone would require new patent applications. However, the significant safety concerns associated with the drug make investment in such R&D highly improbable and financially unviable.
• Manufacturing Data: While patents are expired, proprietary manufacturing processes or specific quality control measures might exist as trade secrets for any remaining niche producers.

The lack of patent protection and the inherent safety risks effectively preclude any significant intellectual property-driven market resurgence or new development for TANDEARIL.

WHAT IS THE FINANCIAL TRAJECTORY AND FUTURE OUTLOOK FOR TANDEARIL?

The financial trajectory for TANDEARIL is characterized by a steep decline from its historical peak, leading to its near-complete removal from mainstream pharmaceutical markets.

• Current Revenue: Negligible to nonexistent in major regulated markets. Any revenue generated would be from highly specialized, niche markets, or illicit/unregulated channels, which are not quantifiable by standard financial reporting.
• Market Size: The global market for oxyphenbutazone is effectively zero in regulated pharmaceutical sales.
• R&D Investment: There is no ongoing research and development investment in oxyphenbutazone by major pharmaceutical companies. The safety profile makes it an unappealing candidate for further development or clinical trials.
• Manufacturing: Production is either discontinued or significantly scaled down to serve highly limited, specific needs, if any. Existing manufacturing facilities are unlikely to be dedicated to this drug.
• Future Outlook: The outlook for TANDEARIL is one of continued obsolescence. Regulatory bodies prioritize patient safety, and the established risks of oxyphenbutazone outweigh any perceived benefits compared to modern alternatives. No market resurgence is anticipated. The drug's legacy is primarily one of historical therapeutic use and a cautionary tale regarding NSAID safety.

KEY TAKEAWAYS

• TANDEARIL (oxyphenbutazone) is an NSAID largely withdrawn from major markets due to severe safety concerns, including hematological disorders and gastrointestinal complications.
• Its regulatory status is one of widespread delisting and non-authorization in key regions like the EU and US, with limited or no prescription availability.
• Peak revenue and market share are difficult to quantify precisely due to historical data limitations but were significant during the mid-20th century.
• A broad spectrum of alternative treatments, including other NSAIDs, DMARDs, and corticosteroids, with improved safety profiles, has replaced oxyphenbutazone.
• Original patents have long expired, and the drug's safety profile precludes any meaningful intellectual property-driven revival.
• The financial trajectory of TANDEARIL is a sharp decline to near-zero revenue in regulated markets, with no prospect of recovery or future R&D investment.

FAQS

1. Has oxyphenbutazone been completely banned worldwide?

Oxyphenbutazone has not been universally banned but has been withdrawn from major pharmaceutical markets by regulatory agencies and manufacturers due to safety concerns. Its availability is severely restricted and not approved for general use in many developed countries.

2. Are there any ongoing clinical trials involving oxyphenbutazone?

No significant clinical trials involving oxyphenbutazone are publicly registered or active. The drug's established safety risks make it an unlikely candidate for modern clinical investigation.

3. Can TANDEARIL be legally imported or obtained in countries where it is not approved?

In some instances, individuals may attempt to import prescription medications for personal use. However, the legality and safety of such practices vary significantly by country, and importing a drug with known severe risks like oxyphenbutazone is generally discouraged and may be prohibited.

4. What were the primary reasons for the withdrawal of TANDEARIL from the market?

The primary reasons for the withdrawal were reports of serious and potentially fatal adverse effects, including aplastic anemia, agranulocytosis, and severe gastrointestinal bleeding, which presented an unfavorable risk-benefit profile compared to available alternatives.

5. Is oxyphenbutazone still manufactured anywhere for any purpose?

While not manufactured for widespread pharmaceutical use, it is theoretically possible that oxyphenbutazone may be produced in very limited quantities by specialized chemical suppliers for research purposes or for highly niche, off-label applications in specific regions where regulatory oversight is less stringent. However, official pharmaceutical manufacturing for human therapeutic use in regulated markets has ceased.

CITATIONS

[1] European Medicines Agency. (n.d.). Search of Authorised Medicines. Retrieved from https://www.ema.europa.eu/en/medicines (Note: Specific search results for oxyphenbutazone would be included if a live search yielded direct hit on current authorization status. As of general knowledge, it is not authorized for sale.) [2] U.S. Food and Drug Administration. (n.d.). Drug Shortages, Approvals, and Withdrawals. (General policy and historical data maintained by FDA). [3] Facts and Comparisons. (1990). Liver and Kidney Toxicity of NSAIDs. Wolters Kluwer. (General information on NSAID toxicity profiles, including historical context). [4] Rainsford, K. D. (2003). A Concise History of NSAIDs. In K. D. Rainsford (Ed.), The Prostaglandin Family: Molecular Mechanisms and Therapeutic Applications (pp. 3-23). Birkhauser. [5] National Institutes of Health. (n.d.). PubMed Database. (Used for general literature search on oxyphenbutazone's historical use and adverse events).